Efficacy and safety of finerenone for treatment of diabetic kidney disease: current knowledge and future perspective.
Vincenzo MarzollaMarco InfanteAndrea ArmaniManfredi RizzoMassimiliano CaprioPublished in: Expert opinion on drug safety (2022)
Pharmacological properties of finerenone and its unique tissue distribution are responsible for a lower risk of hyperkalemia. Therefore, finerenone represents a valuable therapeutic tool in patients with CKD/diabetic kidney disease (DKD). Recent studies have shown that finerenone delays the progression of CKD and reduce cardiovascular events in patients with DKD, highlighting its safety and efficacy in this high-risk population.